Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

Published:2018-09-11 Issue:20 Volume:124 Page:4032-4043
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Dimopoulos Meletios A.¹,Lonial Sagar²,Betts Keith A.³,Chen Clara⁴,Zichlin Miriam L.³,Brun Alexander⁴,Signorovitch James E.³,Makenbaeva Dinara⁴,Mekan Sabeen⁴,Sy Oumar⁴,Weisel Katja⁵,Richardson Paul G.⁶

Affiliation:

1. National and Kapodistrian University of Athens School of Medicine Athens Greece

2. Winship Cancer Institute, Emory University School of Medicine Atlanta Georgia

3. Analysis Group Inc, Boston Massachusetts

4. Bristol‐Myers Squibb Princeton New Jersey

5. University of Tübingen Tübingen Germany

6. Dana‐Farber Cancer Institute Boston Massachusetts

Funder

AbbVie Biotherapeutics

Bristol-Myers Squibb

AbbVie

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31680

Reference24 articles.

1. End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma

2. CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

3. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

4. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone;Cancer Medicine;2024-07

2. Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data;South Russian Journal of Therapeutic Practice;2024-06-24

3. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data;Current Problems in Cancer;2024-06

4. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials;Hematological Oncology;2024-05-31

5. Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study;Internal Medicine;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3